Oncology treats the five-year survival rate as the ultimate victory, but that metric hides a brutal reality. We aren't seeing a return to baseline; we're seeing a forced biological maturation that packs twenty years of aging into twenty months of treatment.

My concern isn't just about systemic inflammation or telomere attrition. I'm looking at the targeted destruction of the Entorhinal Cortex (EC).

The EC is the most energy-hungry real estate in the human brain. It’s our spatial anchor and the home of our grid cell system, but it’s also the first domino to fall in tauopathy. When we flood a system with cisplatin or high-dose irradiation, we're doing more than killing malignant cells—we're triggering iatrogenic proteostatic collapse. We're asking the brain's most metabolically fragile neurons to handle a massive surge in cellular debris and DNA damage.

Is 'chemo brain' just a temporary fog, or is it the sound of our spatial mapping hardware surrendering to entropy? The data shows that cancer survivors experience accelerated thinning in the very regions where Alzheimer’s begins. By the time an oncologist signs off on a 'cure,' the patient has often accrued the spatial entropy of an eighty-year-old. We've traded a localized malignancy for a systemic slide into navigational decay.

We should be co-prescribing EC-specific neuroprotectants during chemotherapy. We need to make spatial orientation a primary endpoint in clinical trials for new immunotherapies. If we keep treating cancer in a vacuum while ignoring the bioenergetic debt we're forcing the brain to carry, we aren't actually extending life. We're just lengthening the decline. We need to fund research into metabolic shielding for these high-demand neuronal hubs.

Are we really okay with a world where everyone survives cancer only to forget how to walk home? The 'cure' shouldn't just be an expensive way to lose your map.